FGAM
EGRX

Financial Gravity Asset Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Financial Gravity Asset Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-247
Closed -$14K – 1742
2019
Q3 		$14K Sell
247
-347
-58% -$19.5K 0.01% 544
2019
Q2 		$33K Buy
+594
New +$31K 0.03% 400

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Financial Gravity Asset Management's EGRX Position: Q4 2019 in Review

Financial Gravity Asset Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2019, closing a stake of 247 shares — an estimated $14K sold.

Financial Gravity Asset Management first reported a position in EGRX in Q2 2019 and held it in 2 quarters. The position peaked at $33K in Q2 2019. 176 funds tracked by Wall St. Rank hold EGRX as of Q4 2019.

  • Financial Gravity Asset Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
  • Financial Gravity Asset Management sold 247 Eagle Pharmaceuticals, Inc. shares in Q4 2019, an estimated $14K.
  • Financial Gravity Asset Management first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2019 and held it in 2 quarters.
  • Financial Gravity Asset Management's Eagle Pharmaceuticals, Inc. position peaked at $33K in Q2 2019.
  • 176 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2019.

Based on Financial Gravity Asset Management's 13F filing for Q4 2019, filed 28 Feb 2020.